NASDAQ · Diagnostics & Research · USD

Burning Rock Biotech Limited (BNR) Stock Analysis

Burning Rock Biotech Limited (BNR) is a Diagnostics & Research stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

BNR

$13.51

+$0.85 (+6.71%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare BNR with… →

BNR Key Statistics

As of Oct 21, 2026

Trading

Open: $13.00
Previous Close: $12.66
Day's Range: 12.66–13.73
52-Week Range: 6.79–41.72
Volume: 20.97K
Beta: 1.29

Valuation

Market Cap: $142.48M
P/E Ratio: unprofitable
P/S ratio: 0.28
EPS (ttm): −0.80

Financials (FY)

Revenue (FY): $539.57M+4.60%
Net Income (FY): −$55.35M
Profit margin: −13.59%
Shares Outstanding: 8.81M
1-Year Return: +33.10%

Dividend and dates

Avg Volume: 30.05K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, BNR closed at $13.51, +33.10% over 1 year.

Burning Rock Biotech Limited (BNR) has a market capitalization of $142.48M.

In fiscal 2025, BNR reported revenue of $539.57M.

BNR Stock Return by Calendar Year

Burning Rock Biotech Limited (BNR) return since Jun 2020: what $10,000 became

1 year: $10,000 $13,310; +33.10%
5 years: $10,000 $1,025; −89.75%
Since Jun 2020: $10,000 $549; −94.51%

If you had invested $10,000 in Burning Rock Biotech Limited (BNR) at the close on June 12, 2020, the earliest close on record here, it would have been worth $549 at the close on October 21, 2026: −94.51% in total, −36.66% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

−6.21%−58.74%−76.39%−58.67%−27.42%+198.52%−32.95%

2020*202120222023202420252026*

Year	Return
2026 (partial year)	−32.95%
2025	+198.52%
2024	−27.42%
2023	−58.67%
2022	−76.39%
2021	−58.74%
2020 (partial year)	−6.21%

As of October 21, 2026.

BNR Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$539.57M	−$55.35M	−10.3%
2024	$515.82M	−$346.63M	−67.2%
2023	$537.44M	−$653.69M	−121.6%
2022	$563.24M	−$971.23M	−172.4%

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$539.57M	$402.91M	−$54.85M	−$55.35M	−10.3%
2024	$515.82M	$362.40M	−$322.43M	−$346.63M	−67.2%
2023	$537.44M	$363.23M	−$669.32M	−$653.69M	−121.6%
2022	$563.24M	$380.04M	−$980.41M	−$971.23M	−172.4%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

BNR Valuation vs Diagnostics & Research Median

Median of 45 stocks

Metric	BNR	Diagnostics & Research median	vs median
P/S ratio	0.28	5.23	0.1x the median
Profit margin	−13.59%	−0.93%	12.7 pts below

Medians across 45 Diagnostics & Research stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Burning Rock Biotech Limited (BNR) carries a market capitalisation of $142.48M. It is classified in the Diagnostics & Research industry, within the Healthcare sector. The company reports 667 employees.

BNR last closed at $13.51 on October 21, 2026. That is +$0.85 (+6.71%) against the previous close. Over the past 52 weeks the price has ranged from $6.79 to $41.72. The latest close sits 98.97% above that 52-week low.

Financial Health

In fiscal 2025, Burning Rock Biotech Limited reported revenue of $539.57M. That is +4.60% against the prior fiscal year, when revenue was $515.82M. The same year closed with a net loss of $55.35M. Profit margin runs at −13.59%. That is 12.7 percentage points below the Diagnostics & Research median of −0.93%. Earnings per share on a trailing basis come to −0.8.

Across the 4 fiscal years on file, revenue moves from $563.24M in 2022 to $539.57M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 0.28. On price-to-sales that is 0.1 times the Diagnostics & Research median of 5.23. The medians here are taken across 45 Diagnostics & Research companies that report the metric.

The reported beta is 1.29. Daily returns over the trailing 6 years annualize to a volatility of 97.85%. Over the trailing twelve months the total return is +33.10%. Across 5 years the annualized return works out at −36.59%.

Growth & Income

The record shows no dividend for BNR.

2026 is still running; the total return is −32.95% year to date. Across the complete calendar years on file, 2025 returned +198.52% and 2022 returned −76.39%. Of the 5 complete calendar years on file, 1 finished higher.

Peer Comparison

Burning Rock Biotech Limited (BNR) operates in the Diagnostics & Research industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Burning Rock Biotech Limited	BNR	$142.48M	—
Thermo Fisher Scientific Inc.	TMO	$256.61B	37.4
Danaher Corporation	DHR	$164.40B	41.7
Natera, Inc.	NTRA	$59.59B	—

The Diagnostics & Research industry average P/E ratio is 37.6x. Burning Rock Biotech Limited has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Diagnostics & Research Stocks

TMO

Thermo Fisher Scientific Inc.

$256.61B

DHR

Danaher Corporation

$164.40B

NTRA

Natera, Inc.

$59.59B

Agilent Technologies, Inc.

$50.12B

IQV

IQVIA Holdings Inc.

$45.53B

WAT

Waters Corporation

$44.92B

View all Diagnostics & Research stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

JNJ

Johnson & Johnson

$621.22B

ABBV

AbbVie Inc.

$503.27B

UNH

UnitedHealth Group Incorporated

$374.30B

MRK

Merck & Co., Inc.

$369.78B

View all Healthcare stocks →

About Burning Rock Biotech Limited

Burning Rock Biotech Limited develops and sells cancer therapy selection tests in the People's Republic of China and the United States. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company offers next-generation sequencing (NGS)-based tissue, liquid biopsy cancer therapy selection, and prognosis prediction tests for various cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its key products include OncoScreen Focus, a multi-gene tumor mutation co-detection test kit for non-small cell lung cancer (NSCLC) patients; OncoScreen Plus, a pan-cancer test for tissue samples; OncoCompass Plus, a corresponding test for liquid biopsy samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; and ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal and related cancers. The company also provides CanCatch, a pre-operative ctDNA detection and post-operative minimal residual disease calling for relapsed patients; OncoMaster, an automatic NGS data analysis and report interpretation machine; as well as Magnis BR-customized version of its key products. In addition, it engages in the facilitation of laboratory equipment sales and sales of reagent kits. The company has a development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, Boehringer Ingelheim, and Merck KGaA. Burning Rock Biotech Limited was founded in 2014 and is headquartered in Guangzhou, the People's Republic of China.

Visit website →